一分钟看懂
这是一项关于肝细胞癌的III 期研究，登记的药物或干预包括JS207；JS007；Toripalimab；Bevacizumab，当前状态为尚未开始招募。登记地点显示中国哈尔滨、上海有研究中心记录。是否仍有名额以及是否值得进一步询问，需要向研究中心确认。
药物或干预
JS207；JS007；Toripalimab；Bevacizumab · III 期
中国哪些地方有记录
以下地点来自登记信息，不代表此刻仍有名额；请向研究中心确认最新情况。
- Harbin Medical University Cancer Hospital · 哈尔滨
- Zhongshan Hospital, Fudan University · 上海
公开的入选条件
- * Voluntarily participate and sign a written informed consent form.
- * Aged 18-75 years, regardless of sex.
- * Histologically/cytologically confirmed HCC, or cirrhosis meeting the American Association for the Study of Liver Diseases (AASLD) clinical diagnostic criteria for HCC.
- * No prior systemic therapy for HCC.
- * At least one measurable lesion per RECIST v1.1 criteria.
- * Child-Pugh liver function grade A or grade B with a score ≤7, and no history of hepatic encephalopathy.
- * Eastern Cooperative Oncology Group (ECOG) performance status (PS) score of 0-1.
- * Expected survival ≥ 12 weeks.
联系前需要确认
请继续确认中心是否启动、疾病分型、既往治疗、检查费用和知情同意安排。
查看登记信息
登记号：NCT07823348；登记信息更新于 2026-09-16。